Search the Newsreel

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Pfizer (PFE) closed up 2.35% at $25.25, outperforming the S&P 500. Investors are anticipating the company's Q3 earnings report on August 4, 2026, with analysts expecting a 12.82% year-over-year decline in earnings per share and a 1.39% decrease in revenue. The stock currently holds …

Pfizer (NYSE:PFE) Shares Gain Pre-Earnings as 7% Dividend Undergoes Cash-Flow Scrutiny

Pfizer (NYSE:PFE) stock saw a modest gain ahead of its Q2 earnings report, as investors scrutinize the sustainability of its nearly 7% dividend amidst cash flow pressures. Preliminary consensus estimates project a decline in second-quarter earnings per share compared to the previous year, and …

Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026

As the industry prepares to gather in Boston this August, leaders from Gilead Sciences, GSK, and Pfizer will headline a plenary session exploring how AI and digital technologies are reshaping biopharmaceutical quality. BOSTON, July 28, 2026 /PRNewswire/ -- As the biopharmaceutical industry prepares to …

PFIZER: Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs

Pfizer reported higher revenue and net profit in Q1 FY27, with EPS increasing to ₹44.69. The company maintained a strong equity position despite exceptional costs in FY26 due to a Cipla agreement and labor code changes. This information is based on an interim report …

PFE|Pfizer Inc|Price:24.660|Chg%:+0.120

This article provides a comprehensive overview of Pfizer Inc. (PFE), detailing its current stock performance, key financial figures, and analyst ratings. It highlights the company's strong fundamentals and high growth potential within the pharmaceuticals industry, noting that its valuation is considered fairly valued. The …

Pfizer shares may move 3% around Aug. 4 earnings release By Investing.com

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Pfizer shares may move 3% around Aug. 4 earnings release

OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

This article first appeared on GuruFocus. Cash Position: Over $300 million in cash, cash equivalents, and restricted cash. Share Repurchase: 9.7 million shares repurchased for approximately $13 million. Diagnostics Revenue: $74.5 million in Q2 2026, including $6.2 million from 4Kscore test. Pharmaceutical Revenue: $89 …

Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer?

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. …

Quantinuum, NVIDIA Corporation, and Pfizer Inc Transformer Models Now Generate Quantum Circuits for Molecular Models

Researchers from Quantinuum, NVIDIA Corporation, and Pfizer Inc. have developed ADAPT-GQE, a generative AI framework that significantly speeds up the creation of quantum circuits for complex molecular modeling. This new approach reduces circuit generation time by an order of magnitude compared to ADAPT-VQE, while …

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Pfizer Japan Inc. and Eisai Co., Ltd. announced a co-promotion agreement for Nurtec® OD Tablet 75mg (rimegepant sulfate hydrate) in Japan, starting September 1, 2026. Nurtec is an oral CGRP receptor antagonist used for both acute treatment and prophylaxis of migraine. This collaboration aims …

Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. …

Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit.

This article discusses a patent dispute where Enanta Pharmaceuticals lost to Pfizer despite filing first, due to a single digit error in their provisional patent application. The Federal Circuit affirmed that Enanta's patent for a coronavirus protease inhibitor was invalid because the provisional application …

OPFI|OppFi Inc|Price:9.060|Chg%:+0.200

This article provides a comprehensive overview of OppFi Inc (OPFI), a tech-enabled specialty finance platform, detailing its stock performance, key financial figures, and analyst ratings. The company is highlighted for its healthy fundamentals, high growth potential, and classification as "fairly valued" despite recent stock …

How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push

Pfizer's TALZENNA plus XTANDI combination drug for prostate cancer has received Priority Review from the FDA for a label expansion into earlier-stage treatment. This move aligns with Pfizer's strategy to focus on high-value oncology therapies as COVID-19 revenues decline and patent expirations loom. While …

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

Pfizer's high 7% dividend yield might seem unsustainable due to a high payout ratio, but the company's robust pipeline and strategic growth initiatives suggest its dividend program is more secure than it appears. Despite past revenue declines, new drug approvals like Padcev's expanded use …

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer PFE announced that the FDA has accepted the supplemental new drug application (sNDA) for Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), for an expanded use in prostate cancer. The sNDA is seeking approval …

Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access

Arkansas is suing 13 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Eli Lilly & Co., alleging they imposed unlawful restrictions on healthcare providers seeking drug discounts under the federal 340B Drug Pricing Program. Attorney General Tim Griffin claims these companies, along with their …

FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use

Pfizer Inc. announced that the FDA has accepted its supplemental New Drug Application for a Priority Review of TALZENNA in combination with XTANDI for men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer. The FDA's Prescription Drug User Fee Act action date is …

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new …

Pfizer's prostate cancer drug combination gets US FDA priority review

Pfizer announced that the U.S. Food and Drug Administration has granted priority review for an expanded approval of its prostate cancer drug combination, Talzenna and Xtandi. This combination targets men with metastatic castration-sensitive prostate cancer who have HRR mutations. The FDA is expected to …

Pfizer trial: TALZENNA combo cut progression-or-death risk 52%

Pfizer announced that the FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA in combination with XTANDI for men with HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The sNDA is supported by Phase 3 TALAPRO-3 trial data showing the …

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in radiographic progression-free survival, with consistent benefit across BRCA and non-BRCA HRR gene alterations NEW YORK, July …

Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond …

OPFI Q1 2026 Earnings: EPS Beats Estimates by 4.76% as Stock Declines - Earnings Cycle Outlook

Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones

Pfizer is navigating a post-COVID transition, with revenue normalizing as sales of pandemic-related products decline significantly from their peak. The company is refocusing on its core pharmaceutical portfolio, including oncology, vaccines, and internal medicine, and emphasizes rebuilding sustainable revenue growth from these areas and …

Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies

BluesightCoveer Image ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer's SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows Bluesight, the leader in hospital intelligence solutions, today announced a partnership with …

Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build

Pfizer's stock, though down over five years, appears fairly priced based on current valuation checks and a P/E ratio of 18.9x, which aligns closely with Simply Wall St's fair P/E of 19.7x. The company's recent oncology and weight-loss drug approvals are balanced by patent …

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season

Pfizer PFE will announce its second-quarter 2026 earnings on Aug. 4, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the company's total revenues. Its key cancer medicines include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi and …

Net income of Pfizer Inc. – BCS:PFECL1

The article provides a title related to the net income of Pfizer Inc. with the stock symbol BCS:PFECL1. It indicates that the market for this particular stock on the Santiago Stock Exchange was closed with no trades. The content is mostly boilerplate from TradingView, …

Pfizer stock trades steady as recent earnings and pipeline updates frame valuation

Pfizer's stock performance reflects a transition from peak Covid-19 revenues to a diversified portfolio. The company's revenue normalized to around $58 billion after exceeding $100 billion during the pandemic, driven by declining Covid-related product sales, while its non-Covid businesses show more stable growth. Valuation …

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

Pfizer (PFE) shares dropped 1.2% in the last trading session, underperforming the broader S&P 500 and Dow. The company is set to release its Q3 earnings on August 4, 2026, with analysts expecting a decline in both EPS and revenue compared to the prior …

Pfizer Suspends Popular Menopause Cream in India

Pfizer has temporarily suspended the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties, significantly reducing estrogen therapy options for women. This move impacts over 620,000 units sold annually and leaves few alternatives for genitourinary syndrome of menopause in …

Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond …

OppFi Inc. (NYSE: OPFI) to delist Class A stock warrants from NYSE

OppFi Inc. (NYSE: OPFI) is delisting its Class A stock warrants from the New York Stock Exchange. These warrants were exercisable for one share of Class A common stock at an exercise price of $11.50 per share. Both OppFi and the NYSE have followed …